Learn More
HIV risk behaviors, susceptibility to HIV acquisition, progression of disease after infection, and response to antiretroviral therapy all vary by age. In those living with HIV, current effective treatment has increased the median life expectancy to >70 years of age. Biologic, medical, individual, social, and societal issues change as one ages with HIV(More)
Based on data from ongoing and completed studies, and to the extent the sponsors have provided requested information, TAG and the undersigned organizations and patient advocates of the community of people living with HIV/AIDS support the full approval of the GSK/Vertex application to FDA of Lexiva® brand 908 (fosamprenavir, NDA 21-XXX) to treat HIV(More)
  • 1